Oculis Holding AG shares plunged >35% after both Phase 3 DIAMOND trials for OCS-01 in diabetic macular edema failed primary ...

In addition to Ocular leadership, event to feature prominent retinal disease experts Dr. Arshad M. Khanani, MD, MA, FASRS; Dr. Lejla Vajzovic, MD, FASRS; and Dr. Darius M. Moshfeghi, MD  Company to ...

Diabetes Week is an annual UK-wide initiative devoted to raising awareness of diabetes and funding research into the ...

Two Phase 3 multicenter trials of OCS-01 (OPTIREACH-enabled topical dexamethasone 15 mg/mL) missed 52-week BCVA and ≥15-letter gain endpoints, prompting abandonment of an FDA NDA for DME. Dosing ...

New research challenges concerns that tirzepatide harms the eyes, finding lower rates of diabetic retinopathy instead.

Ophthalmologist and vitreoretinal specialist Dr. Bunyaporn (Mo) Chandra-Chamnong told members of the Pattaya City Expats Club ...

If you’re living with diabetes, you’re probably already juggling blood sugar checks, medications, diet, and fitness goals. With so much going on, it’s easy to overlook the one thing we often take for ...

Researchers at Hyderabad’s LVPEI have identified distinct gut microbiome patterns linked to diabetic retinopathy, raising the ...

News on Telangana Today, Diabetic Retinopathy (DR) latest news, Diabetic Retinopathy (DR) news, | Telangana Today ...

Men’s Health Week, observed June 15-21, 2026, is designed to encourage men to stop treating preventive health care like an optional side quest. And while annual physicals, cholesterol checks and ...

The primary endpoint of mean change in best corrected visual acuity (BCVA) from baseline to week 52 in both Phase 3 trials was not met The secondary endpoint of retinal thickness showed a substantial ...

Oculis Holding (OCS) stock plunges after late-stage trial failures for the company's lead asset, OCS-01, in diabetic macular edema. Read more here.